Haemonetics (HAE) Tops Q3 EPS by 3c; Sees FY17 Outlook at High End of Range
Tweet
Share
E-mailGet Alerts HAE Hot Sheet
Price: $90.38 -1.05%
Financial Fact:
Cost of goods sold: 116.01M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Cost of goods sold: 116.01M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Haemonetics (NYSE: HAE) reported Q3 EPS of $0.43, $0.03 better than the analyst estimate of $0.40. Revenue for the quarter came in at $227.8 million versus the consensus estimate of $220 million.
Sees FY17 revenues and EPS at high end of range.
For earnings history and earnings-related data on Haemonetics (HAE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c
- Birchtech Corp. (BCHT) Misses Q2 EPS by 7c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
